Home » Newsletters » BioWorld Science

BioWorld Science

July 23, 2009

View Archived Issues

Amantadine improves tardive dyskinesia in schizophrenia patients

Cytokine starts phase I study of oral CPSI-2364, a chemically modified semapimod

LX-1032 receives EMEA orphan drug designation for carcinoid syndrome

Florpiramine F 18 displays potential utility as an imaging biomarker in AD; phase II data disclosed

Foresight reports results from a pilot study of FST-100 in viral conjunctivitis

Compugen reports effects of novel peptide in animal model of retinopathy

Phase III lubiprostone results released for opioid-induced bowel dysfunction

FDA grants approval to ViroMed for phase II clinical trial of VM-202

Histamine antagonist PF-03654746 under development as treatment for AD; phase I data presented

AZD-3480 fails to meet primary outcome in phase IIb trial in mild to moderate AD

Distinct mechanism of action of chimeric variants of the anti-TLR-2 antibody OPN-301 disclosed

CCR2-targeting fusion protein CCL2-LPM developed for the treatment of autoimmune conditions

Actelion describes novel lipoxin receptor agonists

Korea Institute of Science and Technology claims biosynthesized compounds

AVEO and OSI expand drug discovery and translational research collaboration in cancer

Amgen describes novel TRPM8 ligands for the treatment of pain and other diseases

Novel 11beta-HSD1 inhibitors claimed by Vitae Pharmaceuticals for the treatment of diabetes

Concert Pharmaceuticals patents orexin receptor antagonists for the treatment of sleep disorders

FDA approves Incyte's SPA for phase III trial of INCB-18424 in myelofibrosis

Novavax selects RSV vaccine candidate for additional preclinical studies to support IND

Poniard reports results from phase I cardiac safety study of chemotherapy agent picoplatin

FoldRx reports preliminary results from phase II/III clinical study of tafamidis

Bayer and Onyx report results from phase II trial of Nexavar and capecitabine in breast cancer

Critical Outcome Technologies initiates drug discovery program for Alzheimer's disease

Living Cell initiates phase I/IIa clinical trial of diabetes drug DiabeCell

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026